Jump to navigation Jump to search
Clinical data
Routes of
Legal status
Legal status
  • In general: ℞ (Prescription only)
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass631.65 g/mol
3D model (JSmol)

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Efonidipine (INN) is a dihydropyridine calcium channel blocker marketed by Shionogi & Co. of Japan. It was launched in 1995, under the brand name Landel.

It has also been studied in atherosclerosis[1] and acute renal failure.[2]


  1. Toyoda K, Kitahara M, Yamashita T; et al. (1994). "[Effect of efonidipine hydrochloride (NZ-105), a new dihydropyridine calcium antagonist, on the experimental atherosclerosis in cholesterol-fed rabbits]". Nippon Yakurigaku Zasshi (in Japanese). 103 (5): 231–9. PMID 8188119. Unknown parameter |month= ignored (help)
  2. Shudo C, Masuda Y, Sugita H, Tanaka S, Tomita K (1994). "Effects of efonidipine hydrochloride (NZ-105), a new calcium antagonist, against acute renal failure in rats". Gen. Pharmacol. 25 (7): 1451–8. PMID 7896060. Unknown parameter |month= ignored (help)

Template:Calcium channel blockers

Template:WH Template:WS